ACOG Alpha Cognition Inc

$ACOG Essex specializes in small/micro-cap growth equities, focusing on identifying under-the-radar companies right before commercial acceleration. Their team targets revenue-generating healthcare/biotech firms with proprietary assets that are shifting toward profitability. Taking a brand-new 422k-share position indicates that $ACOG's commercial ramp and de-risked profile perfectly align with their fundamental growth strategy!

$ACOG 2026-10-19 13F: Essex Investment Management Co Llc bought a fully new position of 422,858 shrs recently worth 3.806M USD!!

$ACOG The CONVERGE study demonstrates high real-world tolerability with an 80% target dose achievement rate among long-term care patients. This validates ZUNVEYL’s GI-friendly prodrug mechanism, providing crucial commercial leverage for broader physician adoption and PBM coverage.

$ACOG Management is having a virtual meeting with B Riley on Sept. 29. I think this will be a very positive corporate update in my opinion.

$ACOG Amidst another quarter of double digit growth. $14-$20 by EOY. Likely a BO candidate between $30-$50 2027. Higher if it lasts until 2028.

$ACOG Crazy that ACOG is still this unknown. In a year this will be a billion dollar company and that just will be the start.

$ACOG One of the most important points to consider relative to the data seen in the Converge study is that it helps patients get off of and/or reduce their "multi drug cocktail".

$ACOG announced inducement stock options for a new employee under Nasdaq Rule 5635(c)(4).

$ACOG Don't worry guys, I recently sold some shares so ACOG will probably squeeze in a couple of days now :D

$ACOG problem here is the company dont announce anything, no study complete, no ex us approval, no top line results.